AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
company (fewer than 10 staff, mid-high 90% EBIT margin) that expects to be GAAP positive and could use leftover cash for returns including buybacks. Jemperli currently drives roughly $100 million in annual royalties on a $1.4 billion run rate and, with mid-teens quarter-over-quarter growth and multiple upcoming pivotal readouts (including rectal cancer), royalties could approach $400 million if GSK achieves ~$2.7 billion in sales. First Tracks will house development programs (ANB033, rosanilimab, ANB101) and receive a large portion of AnaptysBio's ~$310 million cash, with management weighing a $100M–$200M capitalization to fund operations into 2027–2028 while pursuing strategic financing, FDA interactions, and near-term readouts (ANB033 Phase I-B expected Q4; EoE data in 2027). Interested in AnaptysBio, Inc.? Here are five stocks we like better. Argenx's 28% Surge & Promising Product Propel Investor Confidence AnaptysBio (NASDAQ:ANAB) is preparing to separate its business in
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.MarketBeat
- AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.MarketBeat
- Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/13/26 - Form 4
- ANAB's page on the SEC website